🔎 Trials Near Me

Home › Diffuse Large B-Cell Lymphoma › Ohio

Pag-aaral pangklinika para sa Diffuse Large B-Cell Lymphoma sa Ohio

24 pag-aaral para sa Diffuse Large B-Cell Lymphoma ang naghahanap ng mga kalahok sa mga site sa Ohio.

Mga Lungsod sa Ohio

Opisyal na teksto ng pag-aaral (English)

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

  • Aultman Health Foundation, Canton
  • University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
  • Ohio State University Comprehensive Cancer Center, Columbus
  • at 1 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT06649812

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  • University of Cincinnati Medical Center ( Site 0156), Cincinnati
  • University Hospitals of Cleveland ( Site 0155), Cleveland
  • Fairview Hospital-Moll Cancer Center ( Site 0198), Cleveland
  • at 2 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06890884

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  • University Hospitals Cleveland Medical Center, Cleveland
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06091865

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  • The Ohio State University (OSU), Columbus
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07226843

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • Cleveland Clinic, Cleveland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07101328

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

  • Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07225439

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  • Oncology Hematology Care - Kenwood, Cincinnati
  • University of Cincinnati Medical Center, Cincinnati
  • Cleveland Clinic, Cleveland
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 31, 2026 · NCT06500273

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

  • Ohio State University Comprehensive Cancer Center, Columbus
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT06536049

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • University of Cincinnati (UC) Physicians Company, LLC, Cincinnati
  • Cleveland Clinic, Cleveland
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05826535

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • The Ohio State University Wexner Medical Center, Columbus
Nagre-recruitPhase 1/2
Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06533579

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Oncology Hematology Care Clinical Trials, Cincinnati
  • University of Cincinnati, Cincinnati
  • Cleveland Clinical Taussig Cancer Center, Cleveland
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT07188558

A Long-term Extension Study of PCI-32765 (Ibrutinib)

  • The Ohio State University- James Cancer Hospital, Columbus
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT01804686

DALY II USA/ MB-CART2019.1 for DLBCL

  • The Ohio State University Wexner Medical Center James Cancer, Columbus
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT04792489

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

  • The Ohio state University, Columbus
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 10, 2026 · NCT05077527

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  • Case Western Reserve University, Cleveland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 9, 2026 · NCT06015880

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • University of Cincinnati Medical Center, Cincinnati
  • Cleveland Clinic, Cleveland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT05131022

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Nagre-recruitObservasyonal na pag-aaral
Edad 0 hanggang 38 · Lahat ng kasarian · Na-update Hun 4, 2026 · NCT06131801

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • Gabrail Cancer Center Research,, Canton
Nagre-recruitPhase 1/2
Edad 12 hanggang 95 · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT04329728

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

  • University of Cincinnati, Cincinnati
  • Ohio State University, Columbus
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 13, 2026 · NCT04775745

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  • Case Western Reserve University, Cleveland
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 2, 2026 · NCT05633615

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

  • University Hospitals Cleveland Medical Center, Cleveland
  • The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2025 · NCT05780034

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  • Toledo Clinic Cancer Center, Toledo
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 7, 2023 · NCT04920617

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

  • University of Cincinnati, Cincinnati
  • The Ohio State University Comprehensive Cancer Center, Columbus
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 4, 2022 · NCT04502394

Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.